This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sobi gets rights to Valeant's urea cycle disorder drug Ammonul
22 Feb 2017
In a three-year deal, Valeant Pharmaceuticals International Inc. licensed Swedish Orphan Biovitrum AB (Sobi) exclusive rights to sell and distribute Ammonul (sodium phenyl acetate and sodium benzoate) injection in Europe, the Middle East, and North Africa.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?